PANcreatic CAncer Initial Detection via liquid biopsy

A new publication from the members of PANCAID offers new insights into how the gut metabolome can help distinguish autoimmune pancreatitis from chronic pancreatitis, two diseases with overlapping clinical symptoms but vastly different treatments and outcomes.

Using mass spectrometry-based global metabolomics, researchers identified key metabolic differences, including new potential biomarkers. Especially promising seem:

• Enterolactone
• 4-guanidinobutanoic acid
• Methylthioadenosine sulfoxide

The study also found significant shifts in metabolic pathways related to fatty acids, alkaloids, amino acids, and peptides.

These findings could pave the way toward non-invasive, biomarker-based diagnostic tools for pancreatic diseases, aligning with PANCAID’s broader goal of improving early detection strategies.

👉 Read the full publication here.

Authors: Vladyslav Dovhalyuk, Fan Yang, Sara Nikolic, Miroslav Vujasinovic, Matthias Löhr, Daniel Globisch
Contributing PANCAID parners: Uppsala University and Karolinska Institutet.

On 15 January 2025, PCE, with the support of UEG – United European Gastroenterology, proudly hosted the first PANCAID Stakeholder Dialogue Event at the European Parliament. This important gathering brought together policymakers, clinicians, researchers, and patient advocates to discuss one crucial goal: advancing early detection of pancreatic cancer.
The event featured welcome messages from MEP Nicolás González Casares and Malta’s Minister for Health, Jo Etienne Abela, alongside project insights from Prof. Klaus Pantel and Dr Ioannis Vouldis (European Commission).
Moving patient stories were shared by Ali Stunt, Patrycja Rzadkowska, and Cristina Sandín Garcia, powerfully reminding all attendees why early detection matters. The dialogue continued with an expert roundtable discussion focusing on collaborative strategies to improve outcomes.
Finally, Prof. Núria Malats introduced the PCE Research Map, encouraging stronger research connections across Europe. This event marked a significant step forward in shaping policy, fostering collaboration, and driving innovation in pancreatic cancer detection.
The discussion does not end here. A Call-to-Action document has now been published following this landmark event — highlighting clear steps for policymakers, funding agencies, researchers, and healthcare professionals.

PANCAID is excited to be part of ISMRC 2025, the leading conference on minimal residual cancer. With a dedicated booth and several PANCAID members speaking at the event, we look forward to sharing insights on early detection of pancreatic cancer and connecting with the research community.

If you’re attending, stop by our booth No. 21 to learn more about our work! See you in Nice! 🇫🇷